Accord Healthcare launches Herceptin biosimilar in the UK
Zercepac will be available for HER2-positive breast and gastric cancers
Read More
Tag: herceptin
US nod for Roche’s breast cancer combo
The therapy marks Roche’s first combination of two monoclonal antibodies administered in a single subcutaneous injection
Read More
New early breast cancer option recommended by NICE
The drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had.
Read More
Mundipharma picks up rights to Herceptin biosimilar Tuznue
The deals allows the firm to market and distribute the drug in selected European countries following its approval
Read More
New Herceptin combo could keep breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options.
Read More
Long-term data shows promise in breast cancer biosimilar
The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.
Read More
NICE changes its mind on Perjeta
NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.
Read More
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Read More
Roche’s Kadcyla shows promise in early breast cancer
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
Read More
Herceptin biosimilar Herzuma launched in Europe
Mundipharma announced that its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
Read More
FDA rejects Pfizer’s Herceptin biosimilar
US regulators have issued a complete response letter regarding Pfizer’s filing for a biosimilar version of Roche’s blockbuster cancer drug Herceptin.
Read More
Napp secures distribution rights to Celltrion’s Herzuma
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
